A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Advanced Solid Tumors With and Without Brain Metastases

Interventions

DRUG

ANG1005

IV infusion once every 21 days

Trial Locations (3)

Gabrail Cancer Center, Canton

University of Texas, MD Anderson Cancer Center, Houston

UT Health Science Center, Cancer Therapy and Research Center, San Antonio